What it sells
Discovering drugs that target the DNA regulome
Business model breakdown
Buyer: who owns the budget?
UnverifiedDiscovery and research leads at biotech/pharma companies (access form lists Biotech/Pharma, Academic, Non-profit).
Trigger: what makes them buy now?
Targets with no 3D structure or known pocket (flexible or disordered proteins) that structure-based tools cannot handle.
Workflow: what inputs become what output?
Input a protein sequence, screen billions of compounds with Ptarmigan-1, predict proteome-wide selectivity and site-level engagement, then validate in living cells with MARMOT profiling.
Economics: what it saves and how it charges
Model access and discovery collaborations / profiling services; claims 3.4B compounds x 20,431 proteins top-ligand retrieval in 20 H100 GPU-hours and roughly 5,000x throughput vs Boltz-2. Commercial terms not published.
Distribution: how it reaches customers
Request-access form for commercial discovery collaborations and academic access; no self-serve pricing shown.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.